Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

PPD Acquires China-based CRO Excel To Continue Global Expansion

This article was originally published in PharmAsia News

Executive Summary

SHANGHAI - The global contract research organization PPD has signed an agreement to acquire Excel PharmaStudies, a leading CRO in China, to upgrade its research capability across Asia, the company announced Oct. 27

You may also be interested in...



PPD Opens Vaccine Clinical Research Center In Taizhou: One Step Closer To Its Goal To Become China's Number One Service Provider

SHANGHAI - PPD has been touting the opening of its new Vaccines and Biologics Center of Excellence in Wayne, Pennsylvania, and now the company is pushing its vaccine expansion into China with the launch of a vaccine clinical research center in Taizhou China Medical City

PPD Opens Vaccine Clinical Research Center In Taizhou: One Step Closer To Its Goal To Become China's Number One Service Provider

SHANGHAI - PPD has been touting the opening of its new Vaccines and Biologics Center of Excellence in Wayne, Pennsylvania, and now the company is pushing its vaccine expansion into China with the launch of a vaccine clinical research center in Taizhou China Medical City

BIO Welcomes First Chinese Members: Shanghai Zhangjiang Park And Taizhou Medical City

SHANGHAI - BIO, the largest biotechnology organization with 1,200 members around the world, announced its first two members from China - Zhangjiang Hi-tech Park in Shanghai and China Medical City in Taizhou - during the group's annual convention in Chicago

Related Content

UsernamePublicRestriction

Register

SC143420

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel